Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2025-06-23 00:00:00 ET · period of report 2025-06-18 · accession 0000912282-25-000695 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-23 | 2025-06-18 | QNCX | Thye Dirk | CEO, CMO, Dir | A - Grant | $1.20 | +150.9K | 994.9K | +18% | +$181.1K |
| D | 2025-06-23 | 2025-06-18 | QNCX | Thye Dirk | CEO, CMO, Dir | A - Grant | $0.13 | +150.9K | 150.9K | New | +$19.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-06-18 | A | A | 150,944 | $1.20 | 994,885 | D | — | — | |
| 2 | Derivative | Warrants | 2025-06-18 | A | A | 150,944 | $0.13 | 150,944 | D | $1.20 · 2025-06-18 to 2030-06-18 | 150,944 Common Shares |